8. ハンチントン病 Disease details / Clinical trials / Drug dev / DR info

11C-UCB-J PET-CT
   Universitaire Ziekenhuizen KU Leuven
      2020   -   NCT04701580   Belgium
18F-FDG PET-MR
   Universitaire Ziekenhuizen KU Leuven
      2020   -   NCT04701580   Belgium
20 MG BID OF PF-02545920
   Pfizer
      2015   Phase 2   NCT02342548   Canada;Germany;Poland;United Kingdom;United States
20MG daily citalopram
   University of Iowa
      2005   Phase 2   NCT00271596   United States
31-phosphorus RMN spectroscopy
   Institut National de la Santé Et de la Recherche Médicale, France
      2012   -   NCT01696708   France
5-chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-OXO-N-phenyl-3-quinolinecarboxamide sodium
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
Aavrh10.CAG.HCYP46a1
   Brainvectis
      2022   Phase 1;Phase 2   EUCTR2021-003052-16-FR   France;United States
AB-1001 gene therapy
   Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)
      2022   Phase 1/Phase 2   NCT05541627   France
ACR16
   A. Carlsson Research AB
      2004   -   EUCTR2004-000394-60-SE   Denmark;Sweden
      2004   -   EUCTR2004-000394-60-DK   Denmark;Sweden
   NEUROSEARCH SWEDEN AB
      2008   -   EUCTR2007-004988-22-IT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
   NeuroSearch Sweden AB
      2009   -   EUCTR2007-004988-22-AT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-PT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-GB   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-FR   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-ES   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-DE   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2007-004988-22-BE   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
   Teva Pharmaceutical Industries
      2008   Phase 3   NCT00665223   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
ACR16 10 MG
   Teva Pharmaceutical Industries
      2008   Phase 2/Phase 3   NCT00724048   Canada;United States
ACR16 22.5 MG
   Teva Pharmaceutical Industries
      2008   Phase 2/Phase 3   NCT00724048   Canada;United States
ACR16 45 MG
   Teva Pharmaceutical Industries
      2008   Phase 2/Phase 3   NCT00724048   Canada;United States
ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
Adeno-associated viral vector serotype RH10 containing THE human cholesterol 24-hydroxylase gene
   Brainvectis
      2022   Phase 1;Phase 2   EUCTR2021-003052-16-FR   France;United States
Adeno-associated virus serotype 5 encoding A microrna targeted TO human huntingtin gene
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Germany;Poland;United Kingdom
AFQ056
   Novartis Pharma Services AG
      2009   -   EUCTR2009-011743-39-GB   Germany;United Kingdom
      2009   -   EUCTR2009-011743-39-DE   Germany;United Kingdom;United States
   Novartis Pharmaceuticals
      2009   Phase 2   NCT01019473   Germany;United Kingdom
ALN-HTT02
   Alnylam Pharmaceuticals
      2024   Phase 1   NCT06585449   Canada;Germany;United Kingdom
Alprazolam
   Pfizer
      2009   Phase 1   NCT00975481   Canada
Amantadine
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001930   United States
AMT-130
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Germany;Poland;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-DE   Germany;Poland;United Kingdom
ANTI-parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
ANX005
   Annexon, Inc.
      2020   Phase 2   NCT04514367   United States
Atomoxetine
   University of Iowa
      2005   Phase 2   NCT00368849   United States
Autologous stem cell
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01834053   India
Benerva
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain
Bevantolol hydrochloride
   SOM Biotech
      2018   Phase 2   EUCTR2018-000203-16-ES   Spain
   SOM Innovation Biotech S.A.
      2022   Phase 2   EUCTR2021-003453-28-IT   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
   SOM Innovation Biotech SA (SOM Biotech)
      2022   Phase 2   EUCTR2021-003453-28-FR   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-003453-28-ES   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-003453-28-DE   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
Bevantololo cloridrato
   SOM Innovation Biotech S.A.
      2022   Phase 2   EUCTR2021-003453-28-IT   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
Biostamp npoint device
   University of Rochester
      2020   Phase 2   NCT04201834   United States
Biotin
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain
Biotina
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06147414   France
   University Hospital, Angers
      2017   -   NCT03296176   France
   University Hospital, Montpellier
      2020   -   NCT04012411   France
BN82451B
   Ipsen
      2014   Phase 2   NCT02231580   Germany
   Ipsen Pharma
      2014   Phase 2   EUCTR2013-002899-41-DE   Germany
BN8251B
   Ipsen Pharma
      2014   Phase 2   EUCTR2013-002899-41-DE   Germany
Body composition using A HAND-held body FAT monitor • resting metabolic rate (RMR) using A ventilated hood system
   University of Aberdeen
      2022   -   NCT05668520   United Kingdom
Brain MRI
   University Hospital, Montpellier
      2020   -   NCT04012411   France
Branaplam
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-000105-92-IT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2021   Phase 2   EUCTR2020-000105-92-ES   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-000105-92-LT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-HU   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-FR   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-DE   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 2   NCT05111249   Belgium;Canada;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
Bupropion
   Charite University, Berlin, Germany
      2012   Phase 2   NCT01914965   Germany
BV-101
   Brainvectis
      2022   Phase 1;Phase 2   EUCTR2021-003052-16-FR   France;United States
Calvan tablets 100
   SOM Innovation Biotech SA (SOM Biotech)
      2022   Phase 2   EUCTR2021-003453-28-DE   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
Calvan® 100 MG
   SOM Biotech
      2018   Phase 2   EUCTR2018-000203-16-ES   Spain
Cannabidiol
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   Phase 2   NCT01502046   Spain
CBD
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   Phase 2   NCT01502046   Spain
Cellavita HD higher dose
   Azidus Brasil
      2018   Phase 2   NCT03252535   Brazil
      2017   Phase 1   NCT02728115   Brazil
Cellavita HD lower dose
   Azidus Brasil
      2018   Phase 2   NCT03252535   Brazil
      2017   Phase 1   NCT02728115   Brazil
Cellavita-HD
   Azidus Brasil
      2020   Phase 2/Phase 3   NCT04219241   Brazil
CKD-504
   Chong Kun Dang Pharmaceutical
      2018   Phase 1   NCT03713892   Korea, Republic of
Coenzyme Q10
   Massachusetts General Hospital
      2008   Phase 3   NCT00608881   Australia;Canada;United States
Cognitive evaluation
   University Hospital, Montpellier
      2020   -   NCT04012411   France
COQ10
   Johns Hopkins University
      2010   Phase 2   NCT00920699   United States
Creatine
   National Center for Complementary and Integrative Health (NCCIH)
      2001   Phase 1/Phase 2   NCT00026988   United States
Creatine monohydrate
   Massachusetts General Hospital
      2010   Phase 2   NCT01411163   United States
      2009   Phase 2   NCT01411150   United States
      2009   Phase 3   NCT00712426   Australia;Canada;New Zealand;United States
      2007   Phase 2   NCT00592995   United States
      2005   Phase 2   NCT01412151   United States
Cystagon
   Centre Hospitalier Universitaire d'Angers
      2008   -   EUCTR2007-002977-30-FR   France
Cysteamine bitartrate
   Centre Hospitalier Universitaire d'Angers
      2010   Phase 2;Phase 3   EUCTR2010-019444-39-FR   France
Deep brain stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Deutetrabenazine
   Fundacion Huntington Puerto Rico
      2022   Phase 1   NCT04301726   Puerto Rico
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China
   Vanderbilt University Medical Center
      2021   Phase 2/Phase 3   NCT04713982   United States
   West China Hospital, Sichuan University
      2023   Phase 4   ChiCTR2300077341   China
Dextromethorphan
   The University of Texas Health Science Center, Houston
      2019   Phase 3   NCT03854019   United States
Digoxin
   Pfizer
      2009   Phase 1   NCT00831506   United States
Dimebon
   Medivation, Inc.
      2010   Phase 3   NCT01085266   -
      2009   Phase 3   NCT00920946   Australia;Canada;Denmark;Germany;Sweden;United Kingdom;United States
      2007   Phase 2   NCT00497159   United States
      2006   Phase 1/Phase 2   NCT00387270   United States
   Pfizer
      2009   Phase 1   NCT00975481   Canada
      2009   Phase 1   NCT00831506   United States
      2009   Phase 1   NCT00827034   United States
      2009   Phase 1   NCT00825084   United States
      2009   Phase 1   NCT00824590   United States
Dimebon + dextromethorphan
   Pfizer
      2008   Phase 1   NCT00788047   United States
Dimebon + ketoconazole
   Pfizer
      2009   Phase 1   NCT00931073   United States
Dimebon + omeprazole
   Pfizer
      2009   Phase 1   NCT00931073   United States
Dimebon alone
   Pfizer
      2009   Phase 1   NCT00931073   United States
Dimebon dihydrochloride
   MEDIVATION, INC.
      2010   -   EUCTR2009-018123-32-IT   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2009-011800-44-IT   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
   Medivation, Inc
      2010   -   EUCTR2009-018123-32-SE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2009-018123-32-NL   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2009-018123-32-GB   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2009-018123-32-DK   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2009-018123-32-DE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2009-011800-44-NL   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2009-011800-44-SE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2009-011800-44-GB   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2009-011800-44-DK   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2009-011800-44-DE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom
   Medivation, Inc.
      2007   Phase 2   EUCTR2007-003293-25-GB   United Kingdom
Dimebon IR
   Pfizer
      2009   Phase 1   NCT00990613   United States
Dimebon IR tablet
   Pfizer
      2009   Phase 1   NCT00988624   United States
Dimebon MR1
   Pfizer
      2009   Phase 1   NCT00988624   United States
Dimebon MR2
   Pfizer
      2009   Phase 1   NCT00988624   United States
Dimebon MR3
   Pfizer
      2009   Phase 1   NCT00988624   United States
Dimebon MR4
   Pfizer
      2009   Phase 1   NCT00988624   United States
Dimebon transdermal
   Pfizer
      2009   Phase 1   NCT00990613   United States
Divalproex
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00095355   United States
Egcg
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01357681   Germany
Epigallocatechin-3-gallate
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01357681   Germany
ER2001 injection
   ExoRNA Bioscience
      2023   Early Phase 1   NCT06024265   China
Ethyl icosapent
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom
Ethyl-EPA
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   NCT00146211   Canada;United States
      2005   -   EUCTR2005-002088-98-GB   Germany;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-002088-98-ES   Germany;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom
Ethyl-icosapent
   Amarin Neuroscience Ltd
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom
Fenofibrate
   University of California, Irvine
      2017   Phase 2   NCT03515213   United States
Graft intracerebral OF foetal neurons
   Assistance Publique - Hôpitaux de Paris
      2002   Phase 2   NCT00190450   France
GSK356278
   GlaxoSmithKline
      2011   Phase 1   NCT01602900   United Kingdom
      2011   Phase 1   NCT01573819   Netherlands
Haloperidol 2MG TAB
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China
High doses OF thiamine Y biotin
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2023   Phase 2   NCT04478734   Spain
Hyperium
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2010   Phase 2   EUCTR2009-018119-14-GB   United Kingdom
Idebenone
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China
Imitation (sham) surgery
   UniQure Biopharma B.V.
      2019   Phase 1/Phase 2   NCT04120493   United States
Intra-striatal RAAV5-mihtt
   UniQure Biopharma B.V.
      2021   Phase 1/Phase 2   NCT05243017   Germany;Poland;United Kingdom
      2019   Phase 1/Phase 2   NCT04120493   United States
Intraparenchymal RAAV1 - (MI)RNA HTT
   Voyager Therapeutics
      2021   Phase 1   NCT04885114   -
Isis 443139 10 MG
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom
Isis 443139 120 MG
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom
Isis 443139 30 MG
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom
Isis 443139 60 MG
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom
Isis 443139 90 MG
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom
Laquinimod
   Teva Branded Pharmaceutical Products R&D, Inc.
      2014   Phase 2   NCT02215616   Canada;Czech Republic;Czechia;France;Germany;India;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
Laquinimod capsules 0.5 MG
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
Latrepirdine
   Medivation, Inc.
      2010   Phase 3   NCT01085266   -
LAX-101
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-002088-98-GB   Germany;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-002088-98-ES   Germany;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom
Lithium
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00095355   United States
LMI070
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-000105-92-IT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
   Novartis Farmacéutica S.A.
      2021   Phase 2   EUCTR2020-000105-92-ES   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-000105-92-LT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-HU   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-FR   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-000105-92-DE   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States
LPM3770164 sustained release tablet
   Luye Pharma Group Ltd.
      2024   Phase 1   NCT06474650   China
LPM3770164 sustained release tablet simulant
   Luye Pharma Group Ltd.
      2023   Phase 1   NCT06216054   China
      2022   Phase 1   NCT05238701   China
Lumbar punction
   University Hospital, Montpellier
      2020   -   NCT04012411   France
MBF-015 16 MG oral capsules
   Medibiofarma S.L.
      2024   Phase 2   NCT06469853   Spain
Melatonin
   The University of Texas Health Science Center, Houston
      2021   -   NCT04421339   United States
Memantine
   Jody Corey-Bloom, MD, PhD
      2004   Phase 4   NCT00652457   United States
   University of British Columbia
      2011   Phase 2   NCT01458470   Canada
Metformin
   Instituto de Investigacion Sanitaria La Fe
      2021   Phase 3   NCT04826692   Spain
Minocycline
   FDA Office of Orphan Products Development
      2001   Phase 1/Phase 2   NCT00029874   United States
   Merit Cudkowicz
      2006   Phase 2/Phase 3   NCT00277355   Canada;United States
Moderate doses OF thiamine Y biotin
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2023   Phase 2   NCT04478734   Spain
Mutation IN THE gene
   National Institute of Nursing Research (NINR)
      2001   -   NCT00075140   United States
NAC
   Western Sydney Local Health District
      2024   Phase 2   NCT05509153   Australia
Neflamapimod
   EIP Pharma Inc
      2019   Phase 2   NCT03980938   United Kingdom
   EIP Pharma, Inc.
      2019   Phase 2   EUCTR2018-004840-51-GB   United Kingdom
Nicotinamide riboside
   Oslo University Hospital
      2025   Phase 2   NCT06853743   Norway
Nilotinib 150 MG
   Georgetown University
      2018   Phase 1   NCT03764215   United States
NON invasive prenatal diagnosis
   University Hospital, Montpellier
      2020   -   NCT04698551   France
Olanzapine
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France
OMS643762
   Omeros Corporation
      2014   Phase 2   NCT02074410   United States
OSU6162 similar TO (-)-OSU 6162
   A. Carlsson Research AB
      2014   Phase 2   EUCTR2013-002545-10-SE   Sweden
PBF-999
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2014   Phase 1   NCT02208934   Spain
PBF-999 / 160 MG
   Palobiofarma SL
      2016   Phase 1   NCT02907294   Spain
PBF-999 / 320 MG
   Palobiofarma SL
      2016   Phase 1   NCT02907294   Spain
PBT2
   Prana Biotechnology Limited
      2012   Phase 2   NCT01590888   Australia;United States
PF-02545920
   Pfizer
      2014   Phase 2   NCT02197130   Canada;Germany;Poland;United Kingdom;United States
      2013   Phase 2   NCT01806896   France
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2015   Phase 2   EUCTR2014-004900-31-DE   Canada;Germany;Poland;United Kingdom;United States
      2014   Phase 2   EUCTR2014-001291-56-DE   Canada;Germany;Poland;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2015   Phase 2   EUCTR2014-001291-56-GB   Canada;Germany;Poland;United Kingdom;United States
PL101
   Prilenia Neurotherapeutics Ltd
      2020   Phase 3   EUCTR2020-002822-10-IT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-FR   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
Pridiopidine
   Prilenia Neurotherapeutics Ltd
      2020   Phase 3   EUCTR2020-002822-10-IT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-FR   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
Pridopidina
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
Pridopidine
   Prilenia
      2020   Phase 3   NCT04556656   Austria;Canada;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 1   NCT03019289   Germany
      2015   Phase 2   NCT02494778   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   NCT02006472   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2011   Phase 2   NCT01306929   Canada;United States
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
Pridopidine hydrochloride
   Prilenia Neurotherapeutics Ltd
      2020   Phase 3   EUCTR2020-002822-10-IT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-FR   Austria;Czech Republic;France;Germany;Italy;Netherlands
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;France;Germany;Italy;Netherlands;United Kingdom;United States
PS659
   VICO Therapeutics B.V.
      2023   Phase 1;Phase 2   EUCTR2022-001314-19-DK   Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2023   Phase 1;Phase 2   EUCTR2022-001314-19-DE   Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2022-001314-19-NL   Denmark;Germany;Italy;Netherlands;Spain;United Kingdom
PTC518
   PTC Therapeutics
      2023   Phase 2   NCT06254482   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom
      2022   Phase 2   NCT05358717   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
PTC518 tablet 20 MG
   PTC Therapeutics, INC
      2023   Phase 2   EUCTR2021-003852-18-AT   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-NL   Australia;Austria;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-FR   Australia;Austria;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
PTC518 tablet 5 MG
   PTC Therapeutics, INC
      2023   Phase 2   EUCTR2021-003852-18-AT   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-NL   Australia;Austria;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-FR   Australia;Austria;France;Germany;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003852-18-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States
Quinidine
   The University of Texas Health Science Center, Houston
      2019   Phase 3   NCT03854019   United States
RAAV5-mihtt
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Germany;Poland;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-DE   Germany;Poland;United Kingdom
Ramelteon
   Massachusetts General Hospital
      2009   -   NCT00907595   United States
Resveratrol
   Assistance Publique - Hôpitaux de Paris
      2015   -   NCT02336633   France
RG6042, formerly isis 443139, ionis-httrx
   F. HOFFMANN - LA ROCHE LTD.
      2019   Phase 3   EUCTR2018-002987-14-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-PL   Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-NL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-GB   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-DK   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2017-002471-25-GB   Canada;Germany;United Kingdom
      2018   Phase 2   EUCTR2017-002471-25-DE   Canada;Germany;United Kingdom
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2019   Phase 3   EUCTR2018-003898-94-ES   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
Rilmenidine
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2010   Phase 2   EUCTR2009-018119-14-GB   United Kingdom
Riluzole
   Sanofi
      1999   Phase 3   NCT00277602   -
Risperidone
   University of Rochester
      2020   Phase 2   NCT04201834   United States
Risperidone 1MG TAB
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China
RO 723-4292/F02
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2018-003898-94-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-PL   Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-NL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-GB   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-DK   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2017-002471-25-GB   Canada;Germany;United Kingdom
      2018   Phase 2   EUCTR2017-002471-25-DE   Canada;Germany;United Kingdom
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2019   Phase 3   EUCTR2018-003898-94-ES   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
RO7234292
   Chugai Pharmaceutical Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224757   Asia except Japan;Europe;Japan;North America;Oceania;South America
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2018-003898-94-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-PL   Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-NL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-GB   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-DK   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002987-14-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2017-002471-25-GB   Canada;Germany;United Kingdom
      2018   Phase 2   EUCTR2017-002471-25-DE   Canada;Germany;United Kingdom
   F.Hoffmann-La Roche Ltd
      2023   Phase 2   EUCTR2022-001991-32-PT   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-PL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-FR   Argentina;Australia;Austria;Canada;Denmark;France;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-DK   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-DE   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
   Hoffmann-La Roche
      2019   Phase 1   NCT04000594   Netherlands;United Kingdom
      2019   Phase 3   NCT03842969   Argentina;Australia;Austria;Canada;Chile;Germany;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 3   NCT03761849   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   NCT03342053   Canada;Germany;United Kingdom
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2022-001991-32-ES   Argentina;Australia;Canada;Japan;New Zealand;Spain;United Kingdom
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2019   Phase 3   EUCTR2018-003898-94-ES   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
Rolipram
   GlaxoSmithKline
      2011   Phase 1   NCT01602900   United Kingdom
RP 103
   Centre Hospitalier Universitaire d'Angers
      2010   Phase 2;Phase 3   EUCTR2010-019444-39-FR   France
RP103
   University Hospital, Angers
      2010   Phase 2/Phase 3   NCT02101957   France
SAGE-718
   Sage Therapeutics
      2022   Phase 3   NCT05655520   Canada;United States
      2022   Phase 2   NCT05358821   United States
      2022   Phase 2   NCT05107128   Australia;Canada;United Kingdom;United States
      2019   Phase 1   NCT03787758   United States
SBT-020
   Stealth Bio Therapeutics Inc
      2017   Phase 2   EUCTR2016-003730-25-NL   Netherlands
SD-809
   Auspex Pharmaceuticals, Inc.
      2013   Phase 3   NCT01897896   Australia;Canada;United States
   Teva Pharmaceutical Industries
      2013   Phase 3   NCT01795859   Australia;Canada;United States
Selisistat
   SIENA BIOTECH SPA
      2011   -   EUCTR2011-001131-23-IT   Germany;Italy;United Kingdom
   Siena Biotech SpA
      2011   -   EUCTR2011-001131-23-GB   Germany;Italy;United Kingdom
      2011   -   EUCTR2011-001131-23-DE   Germany;Italy;United Kingdom
SEN0014196
   SIENA BIOTECH SPA
      2011   -   EUCTR2011-001131-23-IT   Germany;Italy;United Kingdom
   Siena Biotech S.p.A.
      2011   Phase 2   NCT01521585   Germany
      2011   Phase 1   NCT01485965   United States
      2011   Phase 1   NCT01485952   Germany
      2009   Phase 1   NCT01521832   United Kingdom
   Siena Biotech SpA
      2011   -   EUCTR2011-001131-23-GB   Germany;Italy;United Kingdom
      2011   -   EUCTR2011-001131-23-DE   Germany;Italy;United Kingdom
SKY-0515
   Skyhawk Therapeutics, Inc.
      2025   Phase 2/Phase 3   NCT06873334   Australia;New Zealand
Sodium phenylbutyrate
   University of Rochester
      2005   Phase 2   NCT00212316   United States
SOM3355
   SOM Biotech
      2018   Phase 2   EUCTR2018-000203-16-ES   Spain
   SOM Innovation Biotech S.A.
      2022   Phase 2   EUCTR2021-003453-28-IT   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
   SOM Innovation Biotech SA (SOM Biotech)
      2022   Phase 2   EUCTR2021-003453-28-FR   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-003453-28-ES   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-003453-28-DE   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
SOM3355 100MG BID
   SOM Biotech SL
      2018   Phase 2   NCT03575676   Spain
SOM3355 200MG BID
   SOM Biotech SL
      2018   Phase 2   NCT03575676   Spain
SOM3355 capsules
   SOM Innovation Biotech SA
      2022   Phase 2   NCT05475483   France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
SPK-10001
   Spark Therapeutics, Inc.
      2025   Phase 1/Phase 2   NCT06826612   United States
SRX246
   Azevan Pharmaceuticals
      2016   Phase 2   NCT02507284   United States
SS-20
   Stealth Bio Therapeutics Inc
      2017   Phase 2   EUCTR2016-003730-25-NL   Netherlands
Tetrabenazine
   Prestwick Pharmaceuticals
      2000   Phase 3   NCT00219804   -
   William Ondo, MD
      2018   Phase 4   NCT02509793   United States
Tetrabenazine withdrawal
   New York Medical College
      2013   Phase 4   NCT01834911   United States
Tetrahydrocannabinol
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   Phase 2   NCT01502046   Spain
THC
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   Phase 2   NCT01502046   Spain
Tiapridal
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France
Tominersen
   Chugai Pharmaceutical Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224757   Asia except Japan;Europe;Japan;North America;Oceania;South America
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2018-003898-94-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2023   Phase 2   EUCTR2022-001991-32-PT   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-PL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-FR   Argentina;Australia;Austria;Canada;Denmark;France;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-DK   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-DE   Argentina;Australia;Austria;Canada;Denmark;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001991-32-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2022-001991-32-ES   Argentina;Australia;Canada;Japan;New Zealand;Spain;United Kingdom
Tominersen 100 MG
   Hoffmann-La Roche
      2023   Phase 2   NCT05686551   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
Tominersen 60 MG
   Hoffmann-La Roche
      2023   Phase 2   NCT05686551   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
Triheptanoin
   INSERM
      2015   Phase 2   EUCTR2014-005112-42-NL   France;Netherlands
      2015   Phase 2   EUCTR2014-005112-42-FR   France;Netherlands
Triheptanoin 1G/KG/DAY
   Institut National de la Santé Et de la Recherche Médicale, France
      2013   Phase 2   NCT01882062   France
Triheptanoin OIL
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2   NCT02453061   France;Netherlands
TV-5600
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
TV-7820
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
Ubiquinol
   University of Rochester
      2009   Phase 1   NCT00980694   United States
Ursodiol
   Oregon Health and Science University
      2007   Phase 1   NCT00514774   United States
UX007
   INSERM
      2015   Phase 2   EUCTR2014-005112-42-NL   France;Netherlands
      2015   Phase 2   EUCTR2014-005112-42-FR   France;Netherlands
Valbenazine
   Neurocrine Biosciences
      2024   Phase 3   NCT06312189   Canada
      2020   Phase 3   NCT04400331   Canada;United States
      2019   Phase 3   NCT04102579   Canada;United States
Vitamin B7
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain
VO659
   VICO Therapeutics B.V.
      2023   Phase 1;Phase 2   EUCTR2022-001314-19-IT   Denmark;Germany;Italy;Netherlands;Spain;United Kingdom
      2023   Phase 1;Phase 2   EUCTR2022-001314-19-DK   Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2023   Phase 1;Phase 2   EUCTR2022-001314-19-DE   Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2022-001314-19-NL   Denmark;Germany;Italy;Netherlands;Spain;United Kingdom
   Vico Therapeutics B. V.
      2023   Phase 1/Phase 2   NCT05822908   Denmark;France;Germany;Israel;Netherlands;Poland;United Kingdom
VX-745
   EIP Pharma, Inc.
      2019   Phase 2   EUCTR2018-004840-51-GB   United Kingdom
VX15/2503
   Vaccinex Inc.
      2015   Phase 2   NCT02481674   Canada;United States
Warfarin
   Pfizer
      2009   Phase 1   NCT00827034   United States
WVE-003
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT05032196   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-004556-15-NL   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-PL   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-IT   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-FR   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-ES   Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-DK   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-DE   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
WVE-120101
   Wave Life Science Ltd.
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
   Wave Life Sciences Ltd.
      2020   Phase 1/Phase 2   NCT04617847   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2017   Phase 1/Phase 2   NCT03225833   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
   Wave Life Sciences UK Limited
      2020   Phase 2   EUCTR2019-003637-42-PL   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2020   Phase 2   EUCTR2019-003637-42-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2020   Phase 2   EUCTR2019-003637-42-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2020   Phase 2   EUCTR2019-003637-42-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2018   Phase 1;Phase 2   EUCTR2016-005095-10-GB   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
WVE-120102
   WAVE Life Sciences Ltd
      2019   Phase 1;Phase 2   EUCTR2016-005142-39-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
   Wave Life Sciences Ltd.
      2019   Phase 1/Phase 2   NCT04617860   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2017   Phase 1/Phase 2   NCT03225846   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
   Wave Life Sciences UK Limited
      2020   Phase 2   EUCTR2019-002178-30-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2020   Phase 2   EUCTR2019-002178-30-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2020   Phase 2   EUCTR2019-002178-30-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2019   Phase 2   EUCTR2019-002178-30-PL   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2016-005142-39-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2016-005142-39-GB   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2016-005142-39-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States
Xenazine
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France
Zoloft 50MG tablet
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China